CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 201 enrolled
Drug / intervention
Brief Behavioral Compliance Enhancement Treatmentbehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03864146
NCT03864146N/ACompleted

A Randomized Trial of Pioglitazone for the Treatment of Alcohol Use Disorder

VA Office of Research and Development·interventional·Posted Mar 6, 2019·Updated Jun 13, 2025

In Brief

A clinical study evaluating Brief Behavioral Compliance Enhancement Treatment for Alcohol Use Disorder. Completed, enrolled 201 participants across 2 sites.

Detailed Summary

Alcohol Use Disorder (AUD) is common among Veterans but medication treatment is used infrequently and the impact of these treatments are small to moderate at best. Pioglitazone, a medication FDA approved for diabetes, has been shown in pre-clinical studies to reduce alcohol. The proposed study will test the efficacy of pioglitazone to reduce alcohol use in a double-blind placebo controlled trial. Investigators plan to compare pioglitazone to placebo in 200 Veterans who have an AUD and who are currently drinking alcohol at two Veterans Affairs Health Care Centers. The primary hypothesis is that Veterans with an AUD who are currently drinking alcohol will have a greater reduction in alcohol use following treatment with pioglitazone compared to those treated with placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedMar 6, 2019
Enrollment StartJul 17, 2019
Primary CompletionMar 29, 2024
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 7.3 years ago

Interventions

Brief Behavioral Compliance Enhancement Treatmentbehavioral

This is a standardized 15-minute intervention that emphasizes medication adherence as a crucial element to change alcohol use behavior.